contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nightingale-applies-for-its-shares-to-be-listed-on-the-main-market-of-nasdaq-helsinki

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Head of Nordic ER Development, Analyst

Antti Luiro

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Interpreted from the original publication with Copilot’s assistance: Traditional cholesterol measurements: LDL, HDL, triglycerides, sometimes ApoB and ApoA1, describe only a part of lipid metabolism. Reference values: are based on population-level studies. For example, LDL < 3 mmol/l is often considered “good,” but individual risk can still be elevated. For instance, LDL might be “normal,” but the number and quality of LDL particles (small, dense LDL particles) can still increase risk. HDL might be high, but its functional quality can be poor. Interpretation problem: values within the reference ranges do not always mean low risk, because the background of the risk is a complex overall picture of metabolism. Nightingale Health’s approach: NH does not only look at traditional cholesterol values but analyzes hundreds of biomarkers from a single blood sample. Broader profile: includes, for example, lipoprotein particle subtypes (different sizes and quantities of LDL and HDL), amino acids, fatty acids, inflammation markers, and energy metabolism metabolites. Risk identification: NH can identify individuals whose traditional values are “normal,” but whose metabolic profile indicates an elevated risk. For example, the ApoB/ApoA1 ratio and LDL particle subtypes can reveal a risk that a mere LDL value does not show.

Various cholesterols are already measured with “normal” blood tests, and cholesterol-lowering treatment is given as needed. Are the reference values too high, or is it that not all risk can be inferred from normal blood test values, even if they are within the limits? A few years ago, I had an NH test at Terveystalo. My cholesterol balance was “average”, and going into details, there were some Apo values, as well as total, LDL, HDL, and VLDL cholesterols, and triglycerides. Can NH find more risk cases or similar from those values and their ratios than other medicine?

Press Release Significant Study: Nightingale Health’s Blood Analysis Helps Prevent 44% More Heart Attacks and Strokes Compared to Current Healthcare Practice December 17, 2025 Nightingale Health Nightingale Health Plc | Press Release | December 17, 2025 at 09:30:00 EET An independent study shows that Nightingale Health’s blood analysis can improve the prevention of heart attacks and strokes by 44% when used in population-level health screenings. The test identifies high-risk individuals not detected by current tools used for identifying disease risks. The study was conducted by world-leading cardiovascular researchers from the University of Cambridge and published in the prestigious main journal of the European Society of Cardiology (European Heart Journal). The study result is based on data from approximately 300,000 middle-aged Britons, which was modeled to assess the impact of adding Nightingale Health’s test to SCORE2, a cardiovascular disease risk calculator commonly used in Europe. Better prevention with Nightingale Health’s test is possible because the blood values analyzed by Nightingale Health more accurately identify individuals who should be recommended cholesterol-lowering treatment. The study states that this improvement would not increase the number of individuals treated per prevented heart attack. “One of the key findings of our study is that adding metabolomics to current cardiovascular health screening could bring significant population-level health benefits if applied widely,” says Professor Michael Inouye, principal investigator of the study from the Cardiovascular Epidemiology Unit at Cambridge. Nightingale Health’s blood analysis is a clinical tool that is scalable for the entire population and has been approved for healthcare use in the European Union, the United Kingdom, Japan, and Singapore. In Finland, the blood analysis is used in national healthcare, and over 200,000 people have already received their test results. In addition to cardiovascular disease risk, Nightingale Health’s technology simultaneously identifies the risk of type 2 diabetes, chronic kidney disease, and fatty liver with a single test, and with comparable or better performance than current healthcare tools used for identifying disease risks. “This study provides extensive evidence that Nightingale Health’s blood analysis can fundamentally improve the prevention of cardiovascular diseases. A 44% improvement in preventing heart attacks and strokes is a significant leap towards a healthier population. Importantly, this groundbreaking result can be achieved by using conventional cholesterol-lowering treatment, prescribing it to those who need it most. The study shows that Nightingale Health’s blood analysis is superior in finding precisely these individuals in a scalable way,” says Teemu Suna, CEO and Founder of Nightingale Health. “For healthcare systems, this means the opportunity to prevent more heart attacks and strokes without increasing the number of treated individuals per prevented heart attack. For doctors, it means having a scalable, evidence-based tool available that reveals hidden risk in patients who appear healthy based on current risk identification methods. For patients, it means a more effective and simpler way to avoid heart attacks and strokes. We are proud to help healthcare systems in Europe and around the world take a big step towards more efficient, proactive, and cost-effective healthcare,” Teemu Suna continues.

A press release is coming out. This study also sounds promising. This stock certainly has potential if it starts to show as cash flow at some point.                   Inderes              Merkittävä tutkimus: Nightingale Healthin verianalyysi auttaa estämään 44 %...    Nightingale Health Oyj | Lehdistötiedote | 17.12.2025 klo 09:30:00 EETRiippumaton tutkimus osoittaa, että Nightingale Healthin verianalyysi voi parantaa sydäninfarktien ja aivohalvausten ehk...

Here are Antti & Antti’s comments on Nightingale’s management team changes.  Nightingale Health announced on Friday that it is reforming its management team composition. With the changes, the scientific director will step down, and the company will recruit a medical director. This news is a continuation of the CFO change announced earlier in the week, and in light of these, Nightingale is now rebuilding its leadership to better support the growth phase of the company’s healthcare business. The background to these changes is, in our view, logical, as Nightingale has already in recent years shifted the focus of its strategy towards the commercial scaling of its technology. The news does not cause immediate pressure for changes to our forecasts.                   Inderes              Nightingalen johtoryhmän muutokset jatkuvat  - Inderes    Uutisten valossa Nightingale uudelleenrakentaa nyt johtoaan tukeakseen paremmin yhtiön terveydenhuollon liiketoiminnan kasvuvaihetta.

A couple of months ago, I pondered that the company’s board is very homegrown for a global growth phase, and indeed, so is the management team. Finally, we are starting to build what is needed for the international growth phase, but the execution is very cautious, and at least a year late. As I already wrote in the options chain, I prefer leadership that boldly builds the future a bit ahead of time, not belatedly. Well, better now than never, but at least a couple of new people also on the board, and more people who have already earned their stripes in the management team!

Damn it. I have a hunch that Barrett is leaving on his own initiative. He is the only person in the company’s management team who has managed to communicate the importance of technology in a way that others besides geeks understand, and Suna has not shown any signs of learning. As a reminder of Barrett’s communication skills, here’s the May webinar I commented on at the time:  \u003e Jeffrey Barrett’s description of the scientific basis of the analysis (starting at 17m30s) is the best description of Nightingale’s differentiation I’ve heard so far - especially better than the CEO’s high-level fluff. Similarly, Charles Alessi’s (starting at 33m) example of data usage in a clinical context is excellently practical. To my knowledge, Nightingale has not communicated things like this before. CEO Suna, on the other hand, has been rambling about the same things for at least seven years, since I first heard him. Those talks haven’t significantly built credibility. https://youtu.be/mb64f6iEMqE I wouldn’t be worried about the continuation of scientific development; they’ve been able to develop science until now. But where are product development, commercial development, and SALES development? Just over a year ago, I considered this a fairly risk-free stock in my portfolio, especially compared to my previous position, but since then, a third of the capital has melted away while the rest of the market has risen by a third. It wasn’t risk-free, and with these steps, the risks don’t seem to be decreasing.

Nightingale Health

The submission of the application for moving to the main list was expected, as the company announced in November that it was looking into it. 

Translation: Original published in Finnish on 03/12/2025 at 06:34 pm EET
<a href="https://www.inderes.se/releases/nightingale-health-plc-applies-for-its-series-b-shares-to-be-listed-on-the-main-market-of-nasdaq-helsinki" target="_blank" rel="noopener">The submission of the application </a>for moving to the main list was expected, as the company announced in November that it was looking into it. Trading in Nightingale&apos;s B shares is expected to commence on the Main Market of Nasdaq Helsinki on Wednesday next week, March 19, and at the same time the shares will be removed from the First North Growth Market Finland marketplace. Nightingale is also still investigating the OTC trading of its shares in the US, and we consider it quite likely that after the main list transfer, the company will apply for an OTC listing later in the spring.
The changes are driven by the internationalization of the company&#x2019;s business. Nightingale has entered into a wide range of international partnerships, many of which have been in the US, so we do not think it is far-fetched to expect investor interest in the US market. In principle, a transfer to the main list and trading on the OTC market would facilitate international investments in the company.
The news has no impact on our view of the stock and we commented more extensively on this earlier in November&#xa0;<a href="https://www.inderes.se/analyst-comments/nightingale-explores-transfer-to-nasdaq-helsinki-main-list-and-otc-trading-in-the-us" target="_blank" rel="noopener">here.</a>

	2024	25e	26e
Revenue	4.4	5.2	8.2
growth-%	4.2 %	19.2 %	58.2 %
EBIT (adj.)	-18.6	-17.3	-16.2
EBIT-% (adj.)	-426.6 %	-332.6 %	-197.1 %
EPS (adj.)	-0.29	-0.27	-0.25
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Nightingale applies for its shares to be listed on the Main Market of Nasdaq Helsinki

Key Estimate Figures07/03

Forum discussions